These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1053 related items for PubMed ID: 16636210

  • 41. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL.
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [Abstract] [Full Text] [Related]

  • 42. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice.
    Caro JJ, Flegel KM, Orejuela ME, Kelley HE, Speckman JL, Migliaccio-Walle K.
    CMAJ; 1999 Sep 07; 161(5):493-7. PubMed ID: 10497604
    [Abstract] [Full Text] [Related]

  • 43. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
    Lip GY, Frison L, Grind M, SPORTIF Investigators.
    J Intern Med; 2008 Jul 07; 264(1):50-61. PubMed ID: 18266660
    [Abstract] [Full Text] [Related]

  • 44. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation.
    Boulanger L, Hauch O, Friedman M, Foster T, Dixon D, Wygant G, Menzin J.
    Ann Pharmacother; 2006 Jun 07; 40(6):1024-9. PubMed ID: 16735649
    [Abstract] [Full Text] [Related]

  • 45. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials.
    Cleland JG, Shelton R, Nikitin N, Ford S, Frison L, Grind M.
    Eur J Heart Fail; 2007 Jun 07; 9(6-7):730-9. PubMed ID: 17360232
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
    Pérez-Gómez F, Alegría E, Berjón J, Iriarte JA, Zumalde J, Salvador A, Mataix L, NASPEAF Investigators.
    J Am Coll Cardiol; 2004 Oct 19; 44(8):1557-66. PubMed ID: 15489085
    [Abstract] [Full Text] [Related]

  • 49. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE.
    N Engl J Med; 2003 Sep 11; 349(11):1019-26. PubMed ID: 12968085
    [Abstract] [Full Text] [Related]

  • 50. Risks of oral anticoagulant therapy with increasing age.
    Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR.
    Arch Intern Med; 2005 Jul 11; 165(13):1527-32. PubMed ID: 16009869
    [Abstract] [Full Text] [Related]

  • 51. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL, Gage BF.
    JAMA; 2005 Feb 09; 293(6):699-706. PubMed ID: 15701911
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy.
    Blackshear JL, Baker VS, Holland A, Litin SC, Ahlquist DA, Hart RG, Ellefson R, Koehler J.
    Arch Intern Med; 1996 Mar 25; 156(6):658-60. PubMed ID: 8629878
    [Abstract] [Full Text] [Related]

  • 54. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.
    Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D.
    Thromb Haemost; 2009 May 25; 101(5):938-42. PubMed ID: 19404548
    [Abstract] [Full Text] [Related]

  • 55. Effect of hypertension on anticoagulated patients with atrial fibrillation.
    Lip GY, Frison L, Grind M, SPORTIF Invetigators.
    Eur Heart J; 2007 Mar 25; 28(6):752-9. PubMed ID: 17289744
    [Abstract] [Full Text] [Related]

  • 56. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY.
    Circ Arrhythm Electrophysiol; 2012 Apr 25; 5(2):312-8. PubMed ID: 22319005
    [Abstract] [Full Text] [Related]

  • 57. Low incidence of hemorrhagic complications of oral anticoagulant therapy in patients with atrial fibrillation in the daily practice of an anticoagulation clinic.
    Poli D, Antonucci E, Lombardi A, Cecchi E, Corsini I, Gensini GF, Abbate R, Prisco D.
    Ital Heart J; 2003 Jan 25; 4(1):44-7. PubMed ID: 12690920
    [Abstract] [Full Text] [Related]

  • 58. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
    Olsson SB, Executive Steering Committee of the SPORTIF III Investigators.
    Lancet; 2003 Nov 22; 362(9397):1691-8. PubMed ID: 14643116
    [Abstract] [Full Text] [Related]

  • 59. Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics.
    Ezekowitz MD.
    Am Heart Hosp J; 2004 Nov 22; 2(4 Suppl 1):31-5. PubMed ID: 15539973
    [Abstract] [Full Text] [Related]

  • 60. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.
    Circulation; 2015 Jan 13; 131(2):157-64. PubMed ID: 25359164
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.